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NAb screening, and no therapy) were included in the model.
Data from pivotal clinical trials, US product labeling, and other
published sources were used to estimate disease progression,
relapse rates, treatment efﬁcacy (reductions in relative risk of
progression/relapse; effect of NAbs on efﬁcacy), adverse events,
therapy discontinuation/switching, costs, and patient utilities.
For each treatment scenario, incremental cost per QALY was
assessed relative to no therapy, and each screening scenario 
was compared to its corresponding “no screening” scenario.
RESULTS: Incremental cost per QALY (lifetime treatment; 3%
discounting) ranged from $75,300 (Avonex) to $135,900
(Betaseron). NAb screening resulted in 10-year cost savings of
US$5100 per patient (Rebif) and US$3000 (Betaseron), versus
US$800 additional cost for Avonex. CONCLUSIONS: Based on
higher occurrence of NAbs with Betaseron and Rebif, universal
NAb screening of patients treated with these agents improves
clinical effectiveness and is cost saving. However, NAb screen-
ing for Avonex-treated patients is cost additive due to Avonex’s
lower immunogenicity.
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WITH MULTIPLE SCLEROSIS
Boulanger L, Friedman M, Dixon D, Menzin J
Boston Health Economics, Inc, Waltham, MA, USA
OBJECTIVE: To assess health care costs among patients with
multiple sclerosis (MS) in the Florida Medicaid program.
METHODS: We employed a retrospective matched cohort
design using administrative claims data for Florida Medicaid
recipients. Patients were included if they had a diagnosis of MS
between July 1, 2001 and June 30, 2002, and were eligible for
Medicaid as of July 1, 2001. Those covered in capitated plans
or dually eligible for Medicare and Medicaid were excluded. The
comparison cohort consisted of MS-free patients matched on
age, gender, and race to the MS group. The excess cost of MS
(in 2002 US dollars) was estimated as the difference in mean
Medicaid payments between the MS group and matched con-
trols. Patients were followed for 12 months unless eligibility ter-
minated earlier. RESULTS: A total of 951 patients with MS met
cohort selection criteria, a prevalence rate of approximately 8
per 10,000 Medicaid eligibles. About one-third of these patients
were dispensed glatiramer acetate or beta-interferon. MS
patients and matched controls (n = 951) averaged 43 years of
age; 78% were female, and 61% were white. Both cohorts had
similar mean Charlson comorbidity scores and low mortality
rates (<3%). Compared to their matched controls, MS patients
were more likely to be hospitalized (33% vs. 20%, respectively),
use nursing home services (15% vs. 3%), or use home health
care services (37% vs. 11%). The annual per-patient excess cost
of MS was estimated to be $11,383 ($20,264 vs. $8,881 for
matched controls). Long-term care accounted for 44% of the
excess costs, followed by medications (28%), and hospitaliza-
tions (14%). CONCLUSIONS: Although MS is relatively rare in
this Medicaid population, the per-patient costs are high. Long-
term care costs are the largest portion of Medicaid payments,
highlighting the disease burden.
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OBJECTIVES: Interferon beta-1a (Avonex®) is efﬁcacious in
delaying clinically deﬁnite multiple sclerosis (CDMS) following
a single demyelinating event (SDE). This study determined the
cost-utility of Avonex® compared to current treatment (CT) in
delaying the onset of CDMS. METHODS: A cost utility analy-
sis (CUA) was performed. The outcome of interest was the
quality adjusted time spent in the pre-CDMS state, termed
quality adjusted monosymptomatic life years (QAMLYs) gained.
A Markov model was developed with all transitional probabili-
ties and utilities derived from the literature. Costs were reported
in 2002 Canadian dollars. Costs and outcomes were discounted
at 5%. A time horizon of 15 years was applied. All uncertain-
ties were tested via univariate and multivariate sensitivity analy-
ses. RESULTS: From the Ministry of Health (MoH) perspective,
the total expected costs per patient over 15 years were $202,000
and $136,000 for Avonex® and CT, respectively. From the soci-
etal perspective, the total expected costs were $380,000 and
$327,000, respectively. Expected QAMLYs gained were 8.47 for
Avonex® and 8.18 for CT. The incremental cost of Avonex® per
QAMLY gained was $227,586 from the MoH perspective and
$189,286 from the societal perspective. The model was sensitive
to the probability of progressing to CDMS, the utilities, and the
analytical time horizon. CONCLUSION: This analysis demon-
strates an improvement in the cost utility of Avonex® compared
to a previously published CUA for CDMS, providing further evi-
dence of the beneﬁts of treatment following a SDE.
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OBJECTIVE: To compare the average direct costs for patients
diagnosed with vascular dementia (VaD) versus Alzheimer’s
disease (AD) from the perspective of the Taiwan National Health
Insurance (NHI) program. METHODS: Using health care claims
data for NHI recipients in the Bureau of National Health Insur-
ance Kao-Ping Branch, Taiwan, we evaluated NHI expenditures
among adults 50 + years of age diagnosed with VaD (ICD-9-CM
290.4X) or AD (ICD-9-CM 331.0) between July 1, 2000 and
December 31, 2002. Patient’s identiﬁcation period spanned from
Jan 1, 2001 through Dec 31, 2002 with a 6-month baseline
periods and 1-year follow up period. Direct costs estimated using
NHI physician fee schedules. Health care utilization and NHI
expenditures (in 2002 NHI reimbursement prices) were calcu-
lated overall and by component of care. Multivariate techniques,
based on regression analyses of the log of total costs, were
employed to adjust for differences between the study cohorts in
sociodemographics. RESULTS: In total, 1450 patients met study
inclusion criteria; Of the 710 were diagnosed with VaD, 41.6%
were women; Of the 740 with AD, 50.7% were women. The
average age for VaD was 76.25 years and 76.79 years for AD.
Relative to AD patients, the burden of comorbidity was higher
among VaD patients, especially for cerebrovascular disease
(43.2% vs. 15.9%), but also for diabetes (5.6% vs. 3.1%) and
chronic pulmonary disease (5.5% vs. 1.4%). Mean monthly
costs per patient were approximately NT$1013 higher for
patients with VaD versus AD (NT$5467 vs. 4454; p < 0.001).
Most of this excess cost were attributed to higher inpatient uti-
lization (84.8%) and mental health services (11.2%). Adjusting
for difference in age, gender, and comorbid conditions between
the two cohorts, mean monthly cost per patient were about
NT$1107 higher in the VaD cohort (NT$3892 vs. 2785; p <
0.001). CONCLUSIONS: Relative to AD patients, VaD have sig-
